1-Methyl-2-oxo-5-phenyl-piperidin | 32246-05-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Methyl-2-oxo-5-phenyl-piperidin
• 英文别名: 1-methyl-5-phenyl-piperidin-2-one；1-Methyl-5-phenyl-piperidin-2-on；1-methyl-5-phenylpiperidin-2-one
• CAS: 32246-05-2
• 化学式: C₁₂H₁₅NO
• 分子量: 189.257
• InChiKey: ASTTXNJRFSDNDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-Methyl-2-oxo-5-phenyl-piperidin 在 platinum(IV) oxide 硫酸 、 氢气 、 溶剂黄146 、 potassium nitrate 作用下， 生成 1-Methyl-5-(4-phenylazo-phenyl)-piperidin-2-one
  参考文献：
  名称：

  Simple Bi- and tricyclic inhibitors of human steroid 5α-reductase

  摘要：

  A number of tricyclic thiolactams, bicyclic lactams, and bicyclic thiolactams have been prepared and evaluated in vitro as inhibitors of types and ? steroid 5 alpha-reductase. The tricycles with an 8-chloro substituent in the C-ring are nM (IC50) inhibitors of type steroid 5 alpha-reductase (SR). In all the cases studied, lactams are more potent than the corresponding thiolactams. Activity against type 2 SR is greatly enhanced by a styryl (or ate) substituent on the aryl ring of the tri- and bicycles and also a related tricyclic aryl acid. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00368-1
• 作为产物：
  描述：

  3-苯基吡啶 在 乙醇 、 铂 作用下， 生成 1-Methyl-2-oxo-5-phenyl-piperidin
  参考文献：
  名称：

  Sugasawa; Kirisawa, Pharmaceutical Bulletin, 1955, vol. 3, p. 190,192

  摘要：

  DOI：

文献信息

• SPIROLACTAM CGRP RECEPTOR ANTAGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150111914A1

  公开（公告）日：2015-04-23

  The present invention is directed to spirolactam analogues which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及螺内酰胺类似物，其为CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。
• HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150087641A1

  公开（公告）日：2015-03-26

  The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及杂环化合物，其是CGRP受体拮抗剂，并且在治疗或预防CGRP参与的疾病，例如偏头痛方面有用。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病方面使用这些化合物和组合物。
• ALIPHATIC SPIROLACTAM CGRP RECEPTOR ANTAGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150203496A1

  公开（公告）日：2015-07-23

  The present invention is directed to aliphatic spirolactam derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical\compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及脂肪族螺内酰胺衍生物，其为CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗CGRP参与的这种疾病中的使用。
• US9227972B2
  申请人：——

  公开号：US9227972B2

  公开（公告）日：2016-01-05
• US9296750B2
  申请人：——

  公开号：US9296750B2

  公开（公告）日：2016-03-29